Device Trial Radar · NCT07058909
Premarket Clinical Safety Assessment of the ELISIO™-HX
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Sep 8, 2025
Primary completion
Feb 25, 2026
Study completion Feb 25, 2026
Sponsor
- Lead sponsor
- Nipro Medical CorporationNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Bright Research Partners
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary safety objective of this study is to evaluate the safety of the use of the high-permeability hemodialyzer series ELISIO™-HX, by showing that the pre-dialysis albumin levels are not affected using the investigational dialyzer. The primary efficacy objective is to evaluate the performance of the use of the high permeability hemodialyzer series ELISIO™-HX, by showing that the clearance rate of middle molecular weight lambda (λ) free light chain (FLC) is improved by using the investigational dialyzer.
Conditions
- Renal Failure
- Acute Renal Failure
- Chronic Renal Failure
- Chronic Kidney Diseases
- End Stage Renal Disease
Interventions
ELISIO™-HX DialyzerDevice
Following consent, participants will undergo a baseline hemodialysis treatment with their currently used dialyzer, the ELISIO-H™, and following the baseline visit will receive hemodialysis with the investigational device, ELISIO™-HX, three times a week for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Level of AlbuminTime frame: Baseline (last blood draw post-dialysis with ELISIO-H) to last blood draw post-dialysis after 12 weeks of treatment with ELISIO-HX
- Reduction Ratio (RR) of Lambda (λ) FLCTime frame: Baseline (last blood draw post-dialysis with ELISIO-H) to last blood draw post-dialysis after 12 weeks of treatment with ELISIO-HX
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Davita Clinical Research
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.